Systemic anti-cancer therapy: management options for people with non-squamous (adenocarcinoma, large cell undifferentiated) carcinoma and non-small-cell carcinoma (non-otherwise specified) – December 2020 update

**EGFR-TK positive**

- Afatinib (TA310) or Dacomitinib (TA595) or Erlotinib (TA258) or Gefitinib (TA192)
- Osimertinib (TA654)

**T790M positive?**

- **Y**
  - Osimertinib (TA653)
  - Platinum doublet chemotherapy* (when using Pemetrexed+Cisplatin as first-line treatment see TA181)
  - Pemetrexed maintenance (TA402 or TA190)

- **N**
  - Atezolizumab (no PD-L1 expression needed) (TA520) or Nivolumab (if PD-L1 >1%) (TA484)
  - Pembrolizumab (if PD-L1 >1%) (TA428)

**ALK positive**

- Ceritinib (TA500)
- Alectinib (TA536)
- Crizotinib (TA406)
- Brigatinib (TA571)
- Ceritinib (TA395)
- Lorlatinib (TA628)

**ROS-1 positive**

- Crizotinib (TA529) or Entrectinib (TA643)

**New addition**

- Osimertinib (TA654)

**Disease progression**

- Cancer Drugs Fund

- This combination/some of these combinations of drugs do not have a UK marketing authorisation for 1 or more indications

- © NICE 2020. All rights reserved. Subject to Notice of rights.